Treatment response to bortezomib in multiple myeloma correlates
with plasma hepatocyte growth factor concentration and bone
marrow thrombospondin concentration

J 2010

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ et. al.

Basic information

Original name

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

Authors

POUR, Luděk (203 Czech Republic, belonging to the institution); Hana ŠVÁCHOVÁ (203 Czech Republic, belonging to the institution); Zdeněk ADAM (203 Czech Republic, belonging to the institution); Martina ALMASI (203 Czech Republic); Dana KRÁLOVÁ (203 Czech Republic); Tomáš BÜCHLER (703 Slovakia); Lucie KOVÁŘOVÁ (203 Czech Republic, belonging to the institution); Marta KREJČÍ (203 Czech Republic, belonging to the institution); Jaroslav MICHÁLEK (203 Czech Republic, belonging to the institution); Miroslav PENKA (203 Czech Republic, belonging to the institution); Jiří VORLÍČEK (203 Czech Republic, belonging to the institution) and Roman HÁJEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

European Journal of Haematology, 2010, 0902-4441

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 2.785

RIV identification code

RIV/00216224:14110/10:00052598

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.1111/j.1600-0609.2009.01396.x

UT WoS

000275768900008

Keywords in English

angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response

Abstract

In the original language

Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

MSM0021622434, plan (intention)

Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

Cite

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ; Tomáš BÜCHLER; Lucie KOVÁŘOVÁ; Marta KREJČÍ; Jaroslav MICHÁLEK; Miroslav PENKA; Jiří VORLÍČEK and Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. European Journal of Haematology. 2010, vol. 84, No 4, p. 332-336. ISSN 0902-4441. Available from: https://doi.org/10.1111/j.1600-0609.2009.01396.x.

@article{944233,
   author = {Pour, Luděk and Šváchová, Hana and Adam, Zdeněk and Almasi, Martina and Králová, Dana and Büchler, Tomáš and Kovářová, Lucie and Krejčí, Marta and Michálek, Jaroslav and Penka, Miroslav and Vorlíček, Jiří and Hájek, Roman},
   article_number = {4},
   doi = {https://doi.org/10.1111/j.1600-0609.2009.01396.x},
   keywords = {angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration},
   url = {http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf},
   volume = {84},
   year = {2010}
}

TY  - JOUR
ID  - 944233
AU  - Pour, Luděk - Šváchová, Hana - Adam, Zdeněk - Almasi, Martina - Králová, Dana - Büchler, Tomáš - Kovářová, Lucie - Krejčí, Marta - Michálek, Jaroslav - Penka, Miroslav - Vorlíček, Jiří - Hájek, Roman
PY  - 2010
TI  - Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
JF  - European Journal of Haematology
VL  - 84
IS  - 4
SP  - 332-336
EP  - 332-336
SN  - 09024441
KW  - angiogenesis
KW  - chemokines
KW  - bortezomib
KW  - multiple myeloma
KW  - therapeutic response
UR  - http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf
N2  - Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.
ER  -

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ; Tomáš BÜCHLER; Lucie KOVÁŘOVÁ; Marta KREJČÍ; Jaroslav MICHÁLEK; Miroslav PENKA; Jiří VORLÍČEK and Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. \textit{European Journal of Haematology}. 2010, vol.~84, No~4, p.~332-336. ISSN~0902-4441. Available from: https://doi.org/10.1111/j.1600-0609.2009.01396.x.

Přehled o publikaci